Compare MSGE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGE | ARQT |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2023 | 2020 |
| Metric | MSGE | ARQT |
|---|---|---|
| Price | $74.24 | $27.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $61.00 | $34.00 |
| AVG Volume (30 Days) | 576.8K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $942,734,000.00 | $376,072,000.00 |
| Revenue This Year | $10.53 | $34.85 |
| Revenue Next Year | $6.53 | $29.39 |
| P/E Ratio | $46.91 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $35.31 | $13.70 |
| 52 Week High | $82.79 | $31.77 |
| Indicator | MSGE | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 62.27 |
| Support Level | $68.93 | $22.09 |
| Resistance Level | $82.79 | $28.80 |
| Average True Range (ATR) | 2.64 | 1.24 |
| MACD | -0.81 | 0.07 |
| Stochastic Oscillator | 10.58 | 51.09 |
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.